Inhibition of 11 β -hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole

Katharina R. Beck¹, Murielle Bächler¹, Anna Vuorinen¹, Sandra Wagner², Muhammad Akram², Ulrich Griesser³, Veronika Temml², Petra Klusonova¹, Hideaki Yamaguchi⁴, Daniela Schuster², Alex Odermatt^{1*}

¹Swiss Center for Applied Human Toxicology and Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, Pharmazentrum, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland. KRB: katharina.beck@unibas.ch; MB: murielle.baechler@stud.unibas.ch; AV: anna.vuorinen1@gmail.com; PK: petra.klusonova@unibas.ch; AO: alex.odermatt@unibas.ch.

²Institute of Pharmacy/Pharmaceutical Chemistry and Center for Molecular Biosciences Innsbruck (CMBI), Computer Aided Molecular Design Group, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria. SW: sandra.wagner@student.uibk.ac.at; MA: muhammad.akram@uibk.ac.at; VT: veronika.temml@uibk.ac.at; DS: daniela.schuster@uibk.ac.at.

³Institute of Pharmacy/Pharmaceutical Technology, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria. UG: ulrich.griesser@uibk.ac.at.

⁴Department of Applied Biological Chemistry, Meijo University, Nagoya 468-8502, Japan. HY: hyamagu@meijo-u.ac.jp.

*Address of correspondence: Prof. Dr. Alex Odermatt, Swiss Center for Applied Human Toxicology and Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
Alex.Odermatt@unibas.ch; Phone: + 41 61 207 15 30; Fax: + 41 61 207 15 15

Abstract

Impaired 11 β -hydroxysteroid dehydrogenase type 2 (11 β -HSD2)-dependent cortisol inactivation can lead to electrolyte dysbalance, hypertension and cardiometabolic disease. Furthermore, placental 11 β -HSD2 essentially protects the fetus from high maternal glucocorticoid levels, and its impaired function has been associated with altered fetal growth and a higher risk for cardiometabolic diseases in later life. Despite its important role, 11 β -HSD2 is not included in current off-target screening approaches. To identify potential 11 β -HSD inhibitors amongst approved drugs, a pharmacophore model was used for virtual screening, followed by biological assessment of selected hits. This led to the identification of several azole fungicides as 11 β -HSD inhibitors, showing a significant structure-activity relationship between azole scaffold size, 11 β -HSD enzyme selectivity and inhibitory potency. A hydrophobic linker connecting the azole ring to the other, more polar end of the molecule was observed to be favorable for 11 β -HSD2 inhibition and selectivity over 11 β -HSD1. The most potent 11 β -HSD2 inhibition, using cell lysates expressing recombinant human 11 β -HSD2, was obtained for itraconazole (IC₅₀ 139 $\pm$ 14 nM), its active metabolite hydroxyitraconazole (IC₅₀ 223 $\pm$ 31 nM) and posaconazole (IC₅₀ 460 $\pm$ 98 nM). Interestingly, experiments with mouse and rat kidney homogenates showed considerably lower inhibitory activity of these compounds toward 11 β -HSD2, indicating important species-specific differences. Thus, 11 β -HSD2 inhibition by these compounds are likely to be overlooked in preclinical rodent studies. Inhibition of placental 11 β -HSD2 by these compounds, in addition to the known inhibition of cytochrome P450 enzymes and P-glycoprotein efflux transport, might contribute to elevated local cortisol levels, thereby affecting fetal programming.

Keywords

11 β -hydroxysteroid dehydrogenase, virtual screening, reproductive toxicity, itraconazole, posaconazole, glucocorticoid

Chemical compounds studied in this article

Albendazole (PubChem CID: 2082); Butaconazole (PubChem CID: 47472); Climbazole (PubChem CID: 37907); Itraconazole (PubChem CID: 55283); Hydroxyitraconazole (PubChem CID: 108222); Ketoconazole (PubChem CID: 47576); Posaconazole (PubChem CID: 468595); Sertaconazole (PubChem CID: 65863); Terconazole (PubChem CID: 441383); Tioconazole (PubChem CID: 5482)

Abbreviations

11 β -HSD2, 11 β -hydroxysteroid dehydrogenase 2; AME, apparent mineralocorticoid excess; androstenedione, Δ^4 -androstene-3,17-dione; CRH, corticotrophin releasing hormone; DHEA, dehydroepiandrosterone; DHT, 5 α -dihydrotestosterone; DMEM, Dulbecco's modified Eagle medium; GR, glucocorticoid receptor; H6PDH, hexose-6-phosphate dehydrogenase; HEK-293, Human Embryonic Kidney-293 cells; HPA, hypothalamic-pituitary-adrenal; MR, mineralocorticoid receptor; OHI, hydroxyitraconazole; P-gp, P-glycoprotein; TLC, thin layer chromatography; VS, virtual screening.

1. Introduction

11 β -hydroxysteroid dehydrogenase 2 (11 β -HSD2) converts potent 11 β -hydroxyglucocorticoids (cortisol, corticosterone) into their inactive 11-keto forms (cortisone, 11-dehydrocorticosterone), thereby controlling tissue-specific activities of mineralocorticoid receptors (MR) and glucocorticoid receptors (GR) [1]. 11 β -HSD2 is essentially involved in the regulation of electrolyte balance, vascular function, and angiogenesis, as well as in the fetal-placental barrier to inactivate cortisol and protect the fetus from high maternal glucocorticoid levels [2, 3].

The consequences of impaired 11 β -HSD2 function are manifested in patients with genetic loss-of-function mutations suffering from apparent mineralocorticoid excess (AME) [2, 4, 5]. In these patients the excessive cortisol-dependent MR activation in the kidney and colon results in hypokalemia, hypernatremia and water retention, leading to severe hypertension characterized by low renin, low aldosterone and increased plasma and urinary cortisol to cortisone ratios. 11 β -HSD2 activity is essential since very early on in life, because birth weights of individuals homozygous/compound heterozygous for *HSD11B2* mutations were found to be significantly lower than those of their unaffected siblings [6]. Milder acquired forms of AME can be caused by inhibition of 11 β -HSD2, for instance upon consumption of considerable amounts of licorice, containing the potent 11 β -HSD inhibitor glycyrrhetic acid (GA) [7].

The exposure to 11 β -HSD2 inhibitors is especially critical during pregnancy. 11 β -HSD2 builds a placental barrier by protecting the fetus from the 5-10 times higher maternal glucocorticoid levels in the course of a normal pregnancy [8-11]. Nevertheless, this barrier is not entirely complete, as a minor proportion of maternal cortisol is able to cross the placenta [11]. Glucocorticoids are important mediators of fetal growth, development and organ maturation. Rising total plasma cortisol levels during pregnancy, peaking in the third trimester at three-fold non-pregnant levels [12], are in parallel with progressive maturation of fetal organs, most notably the stimulation of

1
2
3
4 surfactant production by the lung. However, glucocorticoid administration, especially during late
5
6 gestation, has been associated with reduced birth weight, elevated blood pressure, higher insulin,
7
8 increased distractibility and attention deficit later in life [13-17]. The correlation between low
9
10 birth weight, albeit in normal ranges, and subsequent diseases in adulthood was found to be
11
12 largely independent of confounding life style factors such as smoking or obesity [15]. It has been
13
14 hypothesized that a reduced placental 11 β -HSD2 activity is responsible for the high
15
16 glucocorticoid concentrations reaching the fetus and subsequent programming of disease
17
18 susceptibility [18]. Importantly, low 11 β -HSD2 expression was found to be associated with
19
20 intrauterine growth restriction pregnancies in humans and in rodent models [19-22].
21
22 Determination of osteocalcin concentration in human cord blood samples, which is a sensitive
23
24 marker of glucocorticoid exposure in adult humans, revealed a direct correlation with placental
25
26 11 β -HSD2 activity [23].
27
28

29
30 Treatment of pregnant rats with dexamethasone, which cannot be inactivated by 11 β -HSD2 [24],
31
32 led to lower birth weights and caused HPA axis hyperactivity, hypertension, hyperglycemia and
33
34 increased anxiety behavior [20, 25]. Similarly, administration of the unselective 11 β -HSD
35
36 inhibitor carbenoxolone to pregnant rats resulted in reduced birth weight, and adult offspring
37
38 showed enhanced HPA activity with increased glucocorticoid and CRH levels as well as elevated
39
40 blood pressure [26, 27]. Evidence for the importance of placental 11 β -HSD2 was contributed by
41
42 studies with placentas from 11 β -HSD2-deficient mice showing increased amino acid and reduced
43
44 glucose transport as well as lower expression levels of genes important for angiogenesis [28].
45
46 Furthermore, maternal stress and malnutrition in rats were reported to be able to down regulate
47
48 placental 11 β -HSD2 and program for diseases in adult life [29-31]. Factors including sex
49
50 steroids, nitric oxide, prostaglandins, proinflammatory cytokines, infections and environmental
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 pollutants were shown to have the potential to reduce 11 β -HSD2 activity in studies using
5
6 placental cell lines [32, 33].
7

8
9 Observational studies showed that pregnant Finnish women consuming large amounts of licorice
10
11 (containing the unselective 11 β -HSD inhibitor glycyrrhetic acid) had shorter gestation times
12
13 [34] and gave birth to children with behavioral disturbances and poorer cognitive functions
14
15 coupled with increased HPA axis activity, in a dose-dependent manner [35, 36]. Compromised
16
17 11 β -HSD2 function during pregnancy has also been implicated in preeclampsia, a major cause of
18
19 maternal and perinatal mortality; however, the etiology is poorly understood [37, 38].
20
21

22
23 Due to its important physiological role and the adverse effects observed upon its inhibition, 11 β -
24
25 HSD2 can be considered as an anti-target for drug development (with a few specific exceptions
26
27 where these effects are wanted); however, it is not included in current off-target screening
28
29 approaches. The present study addressed possible inhibitory effects of approved drugs toward
30
31 11 β -HSD2 by performing a virtual screening (VS) of the DrugBank database using an 11 β -HSD
32
33 pharmacophore model. This was followed by a biological evaluation of selected hits, with a focus
34
35 on the azole fungicides itraconazole and posaconazole.
36
37
38
39
40
41
42

43 **2. Materials and methods**

44 *2.1. Chemicals and reagents*

45
46 [1,2,6,7-³H]-cortisol, [2,4,6,7-³H]-estrone and [2,4,6,7-³H]-estradiol were purchased from
47
48 PerkinElmer (Boston, MA, USA), [1,2-³H]-cortisone from American Radiolabeled Chemicals
49
50 (St. Louis, MO), hydroxyitraconazole (OHI) from Carbosynth (Berkshire, UK) and all other
51
52 chemicals from Sigma Aldrich (Buchs, Switzerland) of the highest grade available. Cell culture
53
54 media were obtained from Sigma Aldrich (Buchs, Switzerland).
55
56
57
58
59
60
61
62
63
64
65

2.2. *Pharmacophore modeling and virtual screening*

The 11 β -HSD inhibitor pharmacophore model used for this study was previously reported and validated [39]. The model was initially based on three potent, structurally diverse 11 β -HSD inhibitors [40] and refined with recent literature and novel screening data (model 4new in reference [39], Fig. 1A).

To discover potential 11 β -HSD inhibitors amongst FDA-approved drugs and nutraceuticals, the DrugBank version 3.0 was downloaded as sd file (1543 approved drugs and 84 nutraceuticals) and transformed into a 3D-multiconformational database using the “build database” protocol of Discovery Studio 4.0 (Discovery Studio, Version 4.0, Biovia Inc., San Diego, CA, 2014). For each compound, a maximum of 255 conformers was calculated using fast settings. For the VS, the “search 3D database” protocol with BEST flexible search was used. The DrugBank database was screened with the 11 β -HSD inhibitors model using Discovery Studio 4.0.

2.3. *Cell culture*

Human Embryonic Kidney-293 cells (HEK-293) cells (used at passage number 15-30), human SW-620 colon carcinoma cells (passage number 11-15) and human MCF-7 breast cancer cells (passage number 19-27) were obtained from ATCC (Manassas, VA, USA) and were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 4.5 g/L glucose, 100U/mL penicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES, pH 7.4, and 10% MEM non-essential amino acid solution.

2.4. *Determination of 11 β -HSD activity in cell lysates*

Enzyme activities were determined as described earlier using lysates of HEK-293 cells stably expressing human 11 β -HSD1 and hexose-6-phosphate dehydrogenase (H6PDH; HHH7 clone) or

1
2
3
4 11 β -HSD2 (AT8 clone) [41]. 11 β -HSD1 reductase activity was measured by incubating the
5
6 lysates for 10 min at 37°C in a total volume of 22 μ L containing 200 nM radiolabeled cortisone,
7
8 500 μ M NADPH and test substance or vehicle (DMSO at a maximal concentration of 0.1%).
9
10 11 β -HSD2-dependent oxidation was assessed in the presence of 200 nM radiolabeled cortisol and
11
12 500 μ M NAD⁺. The reactions were stopped by adding an excess amount of unlabeled cortisone
13
14 and cortisol (1:1, 2 mM in methanol). Approximately 20-25% of the substrate were converted to
15
16 the corresponding product. Steroids were separated by thin layer chromatography (TLC) using
17
18 chloroform and methanol (9:1). Conversion of radiolabeled substrate was measured by
19
20 scintillation counting. The substrate conversion was determined and compared to the enzyme
21
22 activity in the control sample.
23
24
25
26
27

28 To exclude irreversible 11 β -HSD2 inhibition by the investigated compounds, HEK cell lysates
29
30 were preincubated with the corresponding compounds for 0, 5 and 20 min at 4°C, followed by
31
32 determination of enzyme activity. Alternatively, lysate were preincubated with the compounds
33
34 for 10 min followed by subsequent dilution (1:2 or 1:4) and determination of enzyme activity
35
36 [42]. Data (mean $\pm$ SD) were normalized to vehicle control (DMSO) and obtained from at least
37
38 three independent experiments.
39
40
41
42
43
44

45 2.5. *Determination of 11 β -HSD2 activity in intact cells*

46 11 β -HSD2 activity measurement in intact SW-620 and MCF-7 cells was determined as described
47
48 earlier [43]. Briefly, 100 000 SW-620 and 50 000 MCF-7 cells per well were seeded in 96-well
49
50 plates. The medium was replaced after 24 h by 40 μ L steroid- and serum-free DMEM (DMEMsf)
51
52 containing either vehicle or inhibitor and 10 μ L medium containing 10 nCi radiolabeled cortisol
53
54 and unlabeled cortisol to reach a final concentration of 50 nM. SW-620 cells were incubated for 4
55
56
57
58
59
60
61
62
63
64
65

h and MCF-7 cells for 5 h at 37°C, followed by analysis of steroid conversion by TLC and scintillation counting

2.6. *Determination of 17 β -HSD1 and 17 β -HSD2 activity in cell lysates*

Determination of 17 β -HSD1 and 17 β -HSD2 activity was conducted as described earlier [44]. Briefly, lysates of HEK-293 cells transiently expressing human 17 β -HSD1 and 17 β -HSD2 were incubated for 10 min at 37°C in a total volume of 22 μ L in the presence 200 nM estrone containing 50 nCi of [2,4,6,7-³H]-estrone and 500 μ M NADPH for 17 β -HSD1, and with 200 nM estradiol containing 50 nCi of [2,4,6,7-³H]-estradiol and 500 μ M NAD⁺ for 17 β -HSD2 activity measurements. Steroids were separated using TLC and substrate conversion determined by scintillation counting. Data (mean $\pm$ SD) were normalized to vehicle control (DMSO) and obtained from at least three independent experiments.

2.7. *Determination of 11 β -HSD activity in mouse and rat kidney homogenates*

Mouse (C57BL6) and rat (Wistar) kidney tissue from adult males were snap frozen in liquid nitrogen and stored at -80°C until further use. For homogenate preparation, frozen tissue was sonicated in homogenization buffer (250 mM sucrose, 10 mM HEPES, pH 7.4; 900 μ L for 100 mg of kidney) and centrifuged at 2 000 $\times$ g, 4°C for 10 min to remove cell debris. The total protein concentration was determined by BCA assay [45]. The homogenates were prediluted to a protein concentration of 3.75 mg of protein/mL (mouse) or 10 mg of protein/mL (rat) in homogenization buffer. Reactions were performed in a total volume of 22 μ L incubation buffer (300 mM NaCl, 20 mM Tris(hydroxymethyl)aminomethane-hydrochloride, 1 mM EDTA, 10% glycerol, pH 7.7) containing 0.075 mg/mL of mouse and 0.2 mg/mL of rat total kidney protein, respectively, as well as 10 μ M of test compound, 50 nM of corticosterone (containing 50 nCi

[1,2,6,7-³H] corticosterone) and 500 μ M NAD⁺ at 37°C for 20 min. Approximately 20-25% of the substrate were converted. The steroids were separated by TLC and conversion of radiolabeled substrate was measured by scintillation counting.

2.8. Docking

Docking was performed using GOLD 5.2 (The Cambridge Crystallographic Data Centre, Cambridge, UK, [46]) based on a crystal structure of 11 β -HSD1 (co-crystallized with (2*R*)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-1-([3-(1*H*-1,2,4-triazol-1-yl)phenyl]sulfonyl)piperazine, PDB code 3HFG [47]) and a homology model for human 11 β -HSD2 [48] and murine 11 β -HSD2 [49]. The PDB entry 3HFG was chosen for two reasons. First, it was the template for generating the homology model of human and murine 11 β -HSD2. Second, the co-crystallized inhibitor is of similar size as some of the investigated antifungals and contains a triazole moiety. It therefore probably constitutes a binding site conformation suitable for docking this class of 11 β -HSD1 inhibitors.

The ligand binding pocket was defined as a sphere with a 10Å radius around the coordinates X = -19.50 Y = 4.00, Z =14.25. ChemPLP was used as scoring function. As workflow validation, redocking of the original ligand was performed using default settings and the best ranked pose deviates from the crystal structure with an RMSD of 0.856 for 11 β -HSD1. As both the homology models for human and murine 11 β -HSD2 were initially based on PDB entry 3HFG, the same coordinates were used to define the binding site for this docking. For human 11 β -HSD2, the docking was additionally repeated setting Arg212 as flexible amino acid. The binding poses were analyzed using LigandScout 4.1 [50] (Inte:Ligand GmbH, Vienna, Austria).

3. Results

3.1. Virtual screening of the DrugBank database using a 11 β -HSD pharmacophore model and virtual hit selection for biological evaluation

Despite its role in the regulation of electrolyte balance and cardiovascular function and its importance during pregnancy to control the *in utero* environment and therefore fetal growth and development, 11 β -HSD2 is not included in current drug off-target screenings. Thus, the present project aimed to evaluate some approved drugs for their ability to interfere with 11 β -HSD2 activity. For this purpose, the FDA-approved small molecule drug entries of the DrugBank database were subjected to VS using a previously developed 11 β -HSD pharmacophore model (Fig. 1A) [39]. This model is not expected to discriminate between 11 β -HSD1 and 11 β -HSD2 inhibitors because no crystal structure is available for 11 β -HSD2 and the model is, at least in part, built based on available 11 β -HSD1 ligands. Of the 1543 DrugBank entries, 101 approved drugs fitted into the model. Not surprisingly, several steroidal compounds (in total 18 hits) including mainly glucocorticoids, were among the hits. Besides, the virtual hit list contained several prostaglandin analogues as well as anti-infective agents, including antifungals, antibiotics and antiparasitic agents. Antifungals were especially represented by the class of azole fungicides, with sertaconazole, butoconazole and tioconazole as virtual hits (Fig. 1B). The majority of antibiotics comprised β -lactam antibiotics and lincosamides, with cloxacillin, flucloxacillin and nafcillin, as well as clindamycin and lincosamycin as representative structural classes. Further virtual hits included members of the classes of antihypertensives/antiarrhythmics, diuretics, lipid lowering drugs, antidiabetics, analgesics and antipsychotics. Several hits from the VS, belonging to the different structural classes mentioned above and available through an in-house chemical repository, were selected for biological assessment.

3.2. *Effect of selected virtual hits and further structurally related compounds on 11 β -HSD activity*

The selected compounds were first tested for their potential to inhibit cortisol to cortisone conversion in lysates of HEK-293 cells stably expressing human 11 β -HSD2. The selectivity over the closely related 11 β -HSD1 was then determined by measuring the effect of the chemicals on the conversion of cortisone to cortisol. The selected steroids (nandrolone), antiarrhythmics (amiodarone), lipid lowering drugs (atorvastatin, simvastatin), diabetics (rosiglitazone), diuretics (ethacrynic acid), analgesics (indomethacine, nabilone), antipsychotics/sedativa (chlorpromazine), the uricosuric probenecid, antiparasitic agents (amodiaquine, chloroquine and pentamidine), β -lactam antibiotics (cloxacillin, flucloxacillin and nafcillin), lincosamides (clindamycin and lincomycin) and the steroid-like antibiotic fusidic acid showed no or weak inhibition (less than 40% inhibition) of 11 β -HSD1 and 11 β -HSD2 enzyme activity at a concentration of 20 μ M (data not shown). However, the azole fungicides sertaconazole, butoconazole and tioconazole showed moderate activity and inhibited 11 β -HSD2 at a concentration of 20 μ M, resulting in 61%, 44% and 50% residual activity, respectively. These azole fungicides were not selective, and they equally well or preferentially inhibited 11 β -HSD1, showing residual enzyme activities of 35%, 48% and 18%, respectively.

Due to their wide use and partial over-the-counter availability, and their previous association with 11 β -HSDs (triadimefon as a substrate of 11 β -HSD1 and ketoconazole as a weak inhibitor of 11 β -HSD1 and 11 β -HSD2 [39, 51]), additional, structurally related azole fungicides were selected for biological testing in order to provide proof of concept in applying pharmacophores as initial filter for the identification of hazardous compound classes [52]. The biological analyses using HEK-293 cell lysates expressing recombinant human enzymes revealed a clear structure-activity relationship between 11 β -HSD selectivity and structural size and shape of the azoles: the larger

the structural size the more potent its inhibitory activity against 11 β -HSD2 and the higher the selectivity over 11 β -HSD1 (Fig. 2). One requirement of high activity was a hydrophobic central region of the azole scaffold linked to a more polar end. The compounds with a smaller scaffold preferentially inhibited 11 β -HSD1. In addition, the subdivision of azoles in imidazole and triazole derivatives revealed a further relationship. Imidazoles such as tioconazole, sertaconazole and butoconazole preferably inhibited 11 β -HSD1 over 11 β -HSD2, whereas triazoles such as terconazole, posaconazole and itraconazole more potently inhibited 11 β -HSD2. Albendazole, possessing a small azole scaffold containing a benzimidazol structure, was inactive against both enzymes. The most potent 11 β -HSD2 inhibition was found for itraconazole and posaconazole, with IC₅₀ values of 139 $\pm$ 14 nM and 460 $\pm$ 98 nM (Fig. 3), respectively, and selectivity over 11 β -HSD1 (Fig. 2). Furthermore, as itraconazole is mainly metabolized to the pharmacologically active OHI, this metabolite was also tested, yielding an IC₅₀ value of 223 $\pm$ 31 nM against 11 β -HSD2. Irreversible 11 β -HSD2 inhibition by itraconazole, OHI and posaconazole was excluded by preincubation experiments; however, preincubation did not alter the inhibitory effect, suggesting a competitive mode of inhibition in line with competition for substrate binding.

3.3. *Selectivity assessment of the azole fungicides over 17 β -HSD1 and 17 β -HSD2*

Although 11 β -HSD2 and 11 β -HSD1 are responsible for the interconversion of the same substrate, i.e. glucocorticoids, they are distant homologs sharing only about 18% sequence identity [53]. In contrast, human 17 β -HSD2 is more closely related to 11 β -HSD2 with about 45% amino acid sequence identity. 17 β -HSD2 is predominantly involved in the metabolism of sex steroid hormones, inactivating estradiol to estrone, testosterone into Δ 4-androstene-3,17-dione (androstenedione), 5 α -dihydrotestosterone (DHT) into 5 α -androstanedione or 5-androstene-3 β ,17 β -diol to dehydroepiandrosterone (DHEA). The reverse reaction of activating the weak

1
2
3
4 estrogen estrone to the potent estradiol and to a minor extent DHEA to 5-androstene-3 β ,17 β -diol
5
6 is catalyzed by 17 β -HSD1. Due to the high expression of 17 β -HSD1 and 17 β -HSD2 in placenta
7
8 [54, 55], itraconazole, OHI and posaconazole were assessed for their potential to inhibit 17 β -
9
10 HSD1 and 17 β -HSD2 enzyme activity in lysates of HEK-293 cells transiently expressing human
11
12 17 β -HSD1 and 17 β -HSD2. None of the compounds inhibited 17 β -HSD1 or 17 β -HSD2 activity
13
14 (data not shown).
15
16
17
18
19
20

21 3.4. *Species-specific 11 β -HSD2 inhibition by the selected azole fungicides*

22

23 Earlier studies emphasized the importance to assess species-specific differences of 11 β -HSD1
24
25 and 11 β -HSD2 inhibitors, especially prior to conducting *in vivo* experiments [43, 51, 56]. Thus,
26
27 prior to designing a rodent study to assess the effect of the selected azole fungicides on
28
29 glucocorticoid inactivation, inhibition of 11 β -HSD2 by itraconazole, OHI and posaconazole was
30
31 further analyzed in rat and mouse kidney homogenates incubated with 50 nM of the rodent
32
33 substrate corticosterone in the absence or presence of 10 μ M test compound. In a qualitative
34
35 comparison to the potent activity against recombinant human 11 β -HSD2, which was expressed in
36
37 HEK-293 cells and measured upon incubation with 200 nM of the human substrate cortisol,
38
39 considerably lower inhibitory activity was detected against the rat and mouse enzymes. The
40
41 different concentrations of corticosterone and cortisol used for rodent and human 11 β -HSD2,
42
43 respectively, reflect the approximately 5-10 fold affinity difference for these substrates [57, 58].
44
45 Itraconazole (Fig. 4A) and OHI (Fig. 4B) were at least 10-fold less potent toward rat and mouse
46
47 11 β -HSD2 compared to the human enzyme, while posaconazole (Fig. 4C) tended to be 2 times
48
49 less active against rat 11 β -HSD2 and was about 4 times less active against mouse 11 β -HSD2.
50
51 Although the activities of the human and rodent enzymes were measured under different
52
53 conditions, considering their different physiological substrates, the data suggest a higher
54
55
56
57
58
59
60
61
62
63
64
65

inhibitory activity of these azole fungicides toward human 11 β -HSD2 compared to the rodent enzymes.

3.5. *Inhibition of 11 β -HSD2 in cell models with endogenous enzyme expression*

To determine the inhibitory potential of itraconazole, OHI and posaconazole in intact cell systems, SW-620 and MCF-7 cells expressing relatively high endogenous 11 β -HSD2 levels [43] were applied. Itraconazole inhibited 11 β -HSD2 in a concentration-dependent manner with IC₅₀ values of 1.07 ± 0.29 μ M in SW-620 and 1.19 ± 0.24 μ M in MCF-7 cells. In contrast to the inhibitory potency ranking observed in lysates of stably transfected HEK-293 cells, OHI was slightly more potent than itraconazole with IC₅₀ values of 0.82 ± 0.18 μ M in SW-620 and 0.68 ± 0.20 μ M in MCF-7 cells, respectively. Posaconazole did not substantially inhibit 11 β -HSD2 activity, resulting in approximately 60% and 40% residual 11 β -HSD2 activity in SW-620 and MCF-7 cells at a concentration of 5 μ M.

3.6. *Predicted binding of selected fungicides to 11 β -HSD1 and 11 β -HSD2*

Docking studies with 11 β -HSD1 showed two important protein-ligand interactions for azole fungicides such as sertaconazole and tioconazole: a hydrophobic contact with Tyr183 and a hydrogen bond of the azole ring with the backbone nitrogen of Ala172 (Fig. 5A). This hydrogen bond interaction was also the only ligand-coordinating hydrogen bond observed in the 11 β -HSD1 crystal structure co-crystallized with a sulfonyl-piperazine inhibitor and thus, presumably essential for the inhibitory activity. In contrast, terconazole does not form any hydrogen bonds with the binding pocket of 11 β -HSD1. Furthermore, docking of itraconazole and posaconazole revealed steric clashes with Thr124, Thr222 and Ala226 of the 11 β -HSD1 substrate binding pocket, providing an explanation for their inactivity towards 11 β -HSD1. However, a major

1
2
3
4 difference between 11 β -HSD1 and 11 β -HSD2 is the shape of the binding site entry. While
5
6 Met233 flanks the binding site entry of 11 β -HSD1, Arg212 replaces this amino acid at the
7
8 analogous position in 11 β -HSD2. The difference in size and electrostatic properties of these
9
10 amino acids likely influences the inhibitory activity. Indeed, all 11 β -HSD2 active compounds
11
12 analyzed formed an interaction with Arg212. Furthermore, the extended azole scaffolds were
13
14 found to form additional interactions in their docking poses with 11 β -HSD2, pointing towards
15
16 tighter binding to the protein. Interestingly, itraconazole and posaconazole did not fit entirely into
17
18 the binding site of 11 β -HSD2 but rather lined the surface next to the binding site entry with their
19
20 azole part (Fig. 5B). Moreover, the additional hydroxyl group of posaconazole was able to form
21
22 several hydrogen bonds with the phosphate moiety of NADPH.
23
24
25
26
27

28 To rationalize the relative selectivity of the three azole compounds to inhibit human 11 β -HSD2,
29
30 they were also docked into the murine homology model [49]. The murine 11 β -HSD2 homology
31
32 model revealed some crucial differences in the amino acid sequence compared to the human 11 β -
33
34 HSD2. Unlike the equivalent Arg212 on human 11 β -HSD2, Arg279 on mouse 11 β -HSD2 was
35
36 not flanking the binding pocket entrance but oriented away (Fig. 5C). Furthermore, part of the
37
38 binding cavity near the cofactor was occupied by Trp276, a residue located outside the binding
39
40 pocket in human 11 β -HSD2, and this residue caused itraconazole to adopt a different angle
41
42 within the binding cavity in the docking simulation. Additionally, the docking poses for
43
44 itraconazole predicted no hydrogen bonds with the protein (Fig. 5D). This missing structural
45
46 anchoring provides an explanation for the weak activity of this fungicide towards murine 11 β -
47
48 HSD2. Interestingly, regarding murine 11 β -HSD2, posaconazole and OHI showed greater
49
50 inhibitory activity than itraconazole. Compared to itraconazole these two fungicides formed
51
52 interactions with the cofactor via their hydroxyl groups (Figure 5E).
53
54
55
56
57
58
59
60
61
62
63
64
65

One important aspect of *in silico*-driven screening studies is the analysis of the predictions and a possible refinement of the model that was used for screening. The screening model performance was very powerful, as all three azole fungicides identified by the model (tioconazole, sertaconazole and butoconazole) inhibited 11 β -HSD1 enzyme activity at a concentration of 20 μ M by at least 50%. However, although itraconazole and posaconazole were represented in the DrugBank, they were not found by the model as virtual hits. A previous refinement study on this model [39], addressed the shape restriction as one major restrictivity aspect. Shape deletion and subsequent VS of all tested compounds, including OHI, with this model retrieved all compounds except for climbazole as hits. For more thorough VS for potential 11 β -HSD inhibitors, the shape-less model version may therefore be more suitable.

4. Discussion

Molecular modeling-based *in silico* approaches are important in drug development for the identification of bioactive molecules. Pharmacophore-based VS is a powerful strategy to enrich potentially active compounds among a large number of test compounds, thereby facilitating the identification of drug lead structures [59]. Such *in silico* tools are also applied in anti-target screenings; however, in contrast to lead compound identification this is more challenging since this approach aims to identify all potentially harmful substances. The present study applied a pharmacophore model based on 11 β -HSD1 crystal structures for VS of the DrugBank database to find approved drugs that might inhibit 11 β -HSD2, an enzyme not included in current off-target screenings during drug development. The goal was to identify, as a first step, structural compound classes inhibiting 11 β -HSD2, followed by a more detailed analysis of a selected compound class including an *in vitro* validation of selected virtual hits.

The pharmacophore model used in this study demonstrated already earlier high predictive power [60], and azole fungicides have been previously associated with 11 β -HSDs: The azole fungicide triadimefon was reported to be a substrate of 11 β -HSD1 (K_m 3.5 μ M), thereby acting as a weak competitive inhibitor (IC_{50} 15 μ M) [51]. Ketoconazole was found to have weak inhibitory effects toward 11 β -HSD1 and 11 β -HSD2 [39, 61]. Thus, this compound class was chosen for further investigations. Biological evaluation revealed several azole fungicides as 11 β -HSD inhibitors, showing a significant structure-activity relationship between azole scaffold size and 11 β -HSD enzyme selectivity and potency of inhibition. The large scaffolds of itraconazole and posaconazole, which were not initial VS hits, potently inhibited 11 β -HSD2 enzyme activity. Compared to terconazole, which was considerably less active on 11 β -HSD2, itraconazole and posaconazole contain an extended hydrophobic central region and an additional triazolone side chain, which may form additional stabilizing interactions with the binding pocket, including Arg212, thereby providing an explanation for the potent inhibition. Thus, the VS approach has proven useful to identify azole fungicides as 11 β -HSD2 inhibitors and to prioritize this compound class for further biological analyses, which were necessary to identify the most potent compounds itraconazole and posaconazole.

Itraconazole and posaconazole are clinically used for the prophylaxis and treatment of systemic mycotic infections and exert their mode of action by inhibiting the biosynthesis of ergosterol, an essential component of the fungal cell membrane [62, 63]. They can be applied for a prolonged period of time, up to years when used as prophylactic treatment, especially in immunosuppressed patients [64]. After oral exposure, itraconazole is extensively metabolized in the liver by cytochrome P450 3A4 (CYP3A4) to its main metabolite OHI, which retains potent 11 β -HSD2 inhibitory activity. Thus, cortisol-dependent MR and GR activation due to prolonged 11 β -HSD2 inhibition may contribute to the observed adverse effects of these fungicides. In contrast to

1
2
3
4 itraconazole, hepatic metabolism of posaconazole plays a minor role and mainly involves
5
6 conjugation by UDP-glucuronyltransferase UGT1A4 [65]. Although posaconazole is not a
7
8 substrate of CYP3A4, it acts like itraconazole and OHI as a potent CYP3A4 inhibitor and it is
9
10 therefore prone to considerable pharmacokinetic interactions with CYP3A4 substrates, including
11
12 glucocorticoids [66, 67]. Inhibition of CYP3A4 by a single dose of itraconazole was shown to
13
14 significantly decrease the formation clearance (CL_f) of the metabolites 6 β -hydroxycortisol and
15
16 6 β -hydroxycortisone [68]. Plasma cortisol and cortisone concentrations were not altered,
17
18 indicating negative feedback regulation by the HPA axis and suggesting that cortisol levels are
19
20 locally increased in CYP3A4 expressing tissues, particularly in the liver. Itraconazole, OHI and
21
22 posaconazole might further promote local glucocorticoid effects by inhibiting P-glycoprotein (P-
23
24 gp) mediated cortisol efflux [69, 70]. Besides its important role in the liver, P-gp expression has
25
26 been detected in the human placenta from the first trimester on towards full-term [71] and P-gp
27
28 was shown *in vitro* to support the placental 11 β -HSD2 glucocorticoid barrier [72].
29
30

31
32 Inhibition of 11 β -HSD2 by itraconazole and posaconazole might impair glucocorticoid
33
34 inactivation in the kidney, colon, vasculature and placenta. Indeed, Denolle et al. reported a case
35
36 study of a patient on long-term itraconazole treatment developing hypokalemia, edema,
37
38 hypertension, low plasma renin and aldosterone concentrations and normal serum cortisol, typical
39
40 symptoms of AME as a result of cortisol-dependent MR activation [73]. Similar side effects
41
42 including hypokalemia, edema, hypertension and mildly reduced aldosterone serum levels were
43
44 described by Sharkey et al. for several patients during long-term itraconazole use [74].
45
46 Importantly, the drug safety sheet of Sporanox® (itraconazole) reports hypokalemia and edema as
47
48 occasionally ($\geq 1/1000$, $< 1/100$ patients) occurring, whereas the safety sheet for the *i.v.* solution of
49
50 Noxafil® (posaconazole) notes hypokalemia as one of the most likely occurring adverse effect
51
52 (22% of the reports) and a rise in blood pressure as frequent ($1/100$, $< 1/10$) [75, 76].
53
54
55
56
57
58
59
60
61
62
63
64
65

Due to the high plasma protein binding capacity of itraconazole (99.8%), OHI (99.6%) and posaconazole ($\geq 98\%$), predominately to albumin, the circulating fraction of unbound drug is low [75, 76]. However, in specific situations the plasma protein binding capacity can be reduced. Pregnancy leads to several metabolic and physiologic changes, including a decrease of serum albumin levels to about half of those in non-pregnant women. Considering this change, the unbound fraction of itraconazole/OHI and of posaconazole in plasma at steady state conditions during 200 mg b.d.i. itraconazole or 400 mg b.d.i posaconazole treatment [75, 77] can be roughly estimated to reach IC_{25} values of itraconazole (78 nM) and posaconazole (237 nM) for 11β -HSD2 as determined in HEK-293 cell lysates. Despite the high plasma protein binding ability, extensive extravascular distribution and accumulation in tissues are of considerable importance for these lipophilic compounds. Itraconazole was found to exceed plasma concentrations in fat tissue approximately 17-fold and in lung, liver, muscle and kidney about 2-3 fold [64]. Less data are available for posaconazole, although it was shown that posaconazole concentrations are 31-42 fold higher in pulmonary alveolar cells compared with plasma [78]. Thus, the concentration of these triazole fungicides might also be elevated in placental tissue compared with plasma and therefore may reach relevant concentrations to inhibit 11β -HSD2 enzyme activity.

Animal studies revealed embryotoxicity and teratogenicity with craniofacial and skeletal anomalies at concentrations exceeding the maximum recommended human dose by 5-20 fold during itraconazole treatment but at lower than therapeutic doses during posaconazole treatment [75, 76]. Therefore, it is recommended to use these drugs in pregnancy only if the benefit outweighs the potential risk. Extrapolation of findings from animal studies to human is often difficult due to species-specific differences. The present study provides evidence for a considerably weaker inhibition of mouse and rat 11β -HSD2 by itraconazole and OHI, and lower activity of posaconazole towards the rodent enzymes. Thus, 11β -HSD2-related effects on

1
2
3
4 electrolyte balance, cardiovascular system and placental barrier function would be detected in
5
6 rodent models only at much higher concentrations than in humans. Furthermore, regarding the
7
8 latter, animal studies might be unreliable due to the highly variable 11 β -HSD2 expression levels
9
10 during gestation between different species. Mouse placental 11 β -HSD2 mRNA drops towards
11
12 late gestation, while rat placental 11 β -HSD2 reduction occurs later and less pronounced. In
13
14 contrast, human placental 11 β -HSD2 levels are rising during gestation (reviewed by [13]).
15
16

17
18 In a prospective cohort study, de Santis *et al.* evaluated first trimester exposure to itraconazole in
19
20 206 pregnant women compared with 207 unexposed controls [79]. The mean duration of the
21
22 therapy was 6.9 ± 6.4 days with a daily dose of 182 ± 63 mg. No statistical difference between
23
24 the exposed and the control group was found in terms of major congenital anomalies, premature
25
26 birth or birth weight, but rates of live births and spontaneous abortion were higher in the exposed
27
28 group. Bar-Oz *et al.* reported in a retrospective cohort study four times higher congenital
29
30 malformation rates after first trimester exposure to itraconazole; however, strongly suggesting
31
32 reporting bias due to retrospective data analysis [80]. The same authors found no difference in the
33
34 rate of malformations compared to the control in a prospective cohort study with 229 women
35
36 exposed to 50-800 mg itraconazole daily throughout 8.5 ± 12.4 days during the first trimester of
37
38 pregnancy [81]. However, the rate live birth and the mean birth weight were lower in the exposed
39
40 group compared to the control. No human data for prenatal posaconazole exposure have been
41
42 published so far.
43
44
45
46
47
48
49

50 Developmental programming implies that an environmental factor affects fetal development
51
52 during a sensitive time window to predispose the fetus towards diseases permanently throughout
53
54 life [15]. A critical parameter includes the duration of the exposure to an environmental factor.
55
56 The mean prenatal itraconazole exposure reported by de Santis *et al.* and Bar-Oz *et al.* was 6.9-
57
58 8.5 days, thus shorter than the 15 days of treatment needed to reach plasma steady-state levels of
59
60
61
62
63
64
65

1
2
3
4 itraconazole. This is important regarding 11β -HSD2 inhibition and thus prenatal programming
5
6 through glucocorticoids. Several investigations found a reduction in birth weight in infants
7
8 exposed to multiple courses of antenatal glucocorticoid therapy when adjusting for gestational
9
10 age [82-84]. In addition, only first trimester itraconazole exposures were examined in the above
11
12 described studies, but the effects of dexamethasone exposure on birth weight in rats was reported
13
14 to be more pronounced when administered during later stages of pregnancy [85]. Chronic
15
16 glucocorticoid treatment in mice was observed to impair the development of the cerebellum
17
18 through inhibition of Sonic hedgehog (Shh) induced proliferation, a pathway important during
19
20 embryonic growth and postembryonic tissue homeostasis. By upregulation of 11β -HSD2
21
22 expression Shh signaling partly antagonized the glucocorticoid-dependent effects, thus
23
24 representing a feedback mechanism [86]. Interestingly, itraconazole, OHI and posaconazole were
25
26 found to inhibit Shh signaling [87-89], which may result in downregulation of 11β -HSD2
27
28 expression, thereby adding to the direct inhibitory effect of these azole fungicides.
29
30
31
32
33
34

35
36 Elevated glucocorticoid levels are known to inhibit angiogenesis, a crucial process during
37
38 placental development that was shown to be inhibited by itraconazole [88, 90, 91]. Insufficient
39
40 placental vascularization has been associated with intrauterine growth restriction, preeclampsia
41
42 and fetal death, both in human and animal studies (reviewed by [92]).
43
44

45
46 In conclusion, itraconazole, OHI and posaconazole were identified as novel potent inhibitors of
47
48 human 11β -HSD2 by VS of the DrugBank database using an 11β -HSD pharmacophore model.
49
50 Inhibition of placental 11β -HSD2 by these azole fungicides might contribute to an elevated local
51
52 increase of cortisol levels, in addition to the known inhibition of cytochrome P450 enzymes and
53
54 P-gp, thereby affecting fetal programming. Due to the observed species-specific differences, the
55
56 consequences of placental 11β -HSD2 inhibition may have been overlooked in preclinical studies
57
58
59
60
61
62
63
64
65

1
2
3
4 using rodents, although similar biological responses might be detected in rodents, albeit at higher
5
6 concentrations.
7
8
9

10 11 **Conflicts of Interest** 12

13
14 The authors declare no conflict of interest.
15
16
17

18 19 **Acknowledgements** 20

21 This work was supported by the Swiss National Science Foundation No 31003A-159454, the
22
23 Austrian Science Fund (P26782), the Swiss Center for Applied Human Toxicology (SCAHT) and
24
25 the Swiss Federal Office of Public Health (FOPH). A.O. was supported as Chair for Molecular
26
27 and Systems Toxicology by the Novartis Research Foundation. D.S. is a Ingeborg Hochmair
28
29 Professor at the University of Innsbruck. We thank Prof. Thierry Langer, University of Vienna,
30
31 and Inte:Ligand GmbH for providing the LigandScout software.
32
33
34
35
36
37

38 39 **References** 40

- 41 [1] A. Odermatt, D.V. Kratschmar, Tissue-specific modulation of mineralocorticoid receptor
42 function by 11 β -hydroxysteroid dehydrogenases: An overview, *Mol Cell Endocrinol* 350(2)
43 (2012) 168-86.
44
45 [2] P. Ferrari, The role of 11 β -hydroxysteroid dehydrogenase type 2 in human hypertension,
46 *Biochim Biophys Acta* 1802 (2010) 1178-87.
47
48 [3] P.C. White, T. Mune, A.K. Agarwal, 11 β -Hydroxysteroid dehydrogenase and the syndrome
49 of apparent mineralocorticoid excess, *Endocr Rev* 18(1) (1997) 135-56.
50
51 [4] M.I. New, L.S. Levine, E.G. Biglieri, J. Pareira, S. Ulick, Evidence for an unidentified steroid
52 in a child with apparent mineralocorticoid hypertension, *J Clin Endocrinol Metab* 44(5) (1977)
53 924-33.
54
55
56
57
58
59
60
61
62
63
64
65

- [5] T. Mune, F.M. Rogerson, H. Nikkila, A.K. Agarwal, P.C. White, Human hypertension caused by mutations in the kidney isozyme of 11 β -hydroxysteroid dehydrogenase, *Nat Genet* 10(4) (1995) 394-9.
- [6] S. Dave-Sharma, R.C. Wilson, M.D. Harbison, R. Newfield, M.R. Azar, Z.S. Krozowski, J.W. Funder, C.H. Shackleton, H.L. Bradlow, J.Q. Wei, J. Hertecant, A. Moran, R.E. Neiberger, J.W. Balfe, A. Fattah, D. Daneman, H.I. Akkurt, C. De Santis, M.I. New, Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess, *J Clin Endocrinol Metab* 83(7) (1998) 2244-54.
- [7] E.P. Gomez-Sanchez, C.E. Gomez-Sanchez, Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone, *Am J Physiol* 263(6 Pt 1) (1992) E1125-30.
- [8] I.Z. Beitins, F. Bayard, I.G. Ances, A. Kowarski, C.J. Migeon, The metabolic clearance rate, blood production, interconversion and transplacental passage of cortisol and cortisone in pregnancy near term, *Pediatr Res* 7(5) (1973) 509-19.
- [9] R. Gitau, A. Cameron, N.M. Fisk, V. Glover, Fetal exposure to maternal cortisol, *Lancet* 352(9129) (1998) 707-8.
- [10] R.W. Brown, K.E. Chapman, Y. Kotelevtsev, J.L. Yau, R.S. Lindsay, L. Brett, C. Leckie, P. Murad, V. Lyons, J.J. Mullins, C.R. Edwards, J.R. Seckl, Cloning and production of antisera to human placental 11 β -hydroxysteroid dehydrogenase type 2, *Biochem J* 313 (Pt 3) (1996) 1007-17.
- [11] R. Benediktsson, A.A. Calder, C.R. Edwards, J.R. Seckl, Placental 11 β -hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure, *Clin Endocrinol (Oxf)* 46(2) (1997) 161-6.
- [12] C. Jung, J.T. Ho, D.J. Torpy, A. Rogers, M. Doogue, J.G. Lewis, R.J. Czajko, W.J. Inder, A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum, *J Clin Endocrinol Metab* 96(5) (2011) 1533-40.
- [13] A. Harris, J. Seckl, Glucocorticoids, prenatal stress and the programming of disease, *Horm Behav* 59(3) (2011) 279-89.
- [14] E.C. Cottrell, J.R. Seckl, M.C. Holmes, C.S. Wyrwoll, Foetal and placental 11 β -HSD2: a hub for developmental programming, *Acta Physiol (Oxf)* 210(2) (2014) 288-95.
- [15] D.J. Barker, The developmental origins of adult disease, *J Am Coll Nutr* 23(6 Suppl) (2004) 588S-595S.

- [16] D.I. Phillips, D.J. Barker, C.H. Fall, J.R. Seckl, C.B. Whorwood, P.J. Wood, B.R. Walker, Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome?, *J Clin Endocrinol Metab* 83(3) (1998) 757-60.
- [17] N.P. French, R. Hagan, S.F. Evans, M. Godfrey, J.P. Newnham, Repeated antenatal corticosteroids: size at birth and subsequent development, *Am J Obstet Gynecol* 180(1 Pt 1) (1999) 114-21.
- [18] J.R. Seckl, Prenatal glucocorticoids and long-term programming, *Eur J Endocrinol* 151 Suppl 3 (2004) U49-62.
- [19] M. Shams, M.D. Kilby, D.A. Somerset, A.J. Howie, A. Gupta, P.J. Wood, M. Afnan, P.M. Stewart, 11 β -hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction, *Hum Reprod* 13(4) (1998) 799-804.
- [20] R. Benediktsson, R.S. Lindsay, J. Noble, J.R. Seckl, C.R. Edwards, Glucocorticoid exposure in utero: new model for adult hypertension, *Lancet* 341(8841) (1993) 339-41.
- [21] J. Dy, H. Guan, R. Sampath-Kumar, B.S. Richardson, K. Yang, Placental 11 β -hydroxysteroid dehydrogenase type 2 is reduced in pregnancies complicated with idiopathic intrauterine growth Restriction: evidence that this is associated with an attenuated ratio of cortisone to cortisol in the umbilical artery, *Placenta* 29(2) (2008) 193-200.
- [22] C.L. McTernan, N. Draper, H. Nicholson, S.M. Chalder, P. Driver, M. Hewison, M.D. Kilby, P.M. Stewart, Reduced placental 11 β -hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms, *J Clin Endocrinol Metab* 86(10) (2001) 4979-83.
- [23] R. Benediktsson, J. Brennand, L. Tibi, A.A. Calder, J.R. Seckl, C.R. Edwards, Fetal osteocalcin levels are related to placental 11 β -hydroxysteroid dehydrogenase activity in humans, *Clin Endocrinol (Oxf)* 42(5) (1995) 551-5.
- [24] A.G. Rebuffat, S. Tam, A.R. Nawrocki, M.E. Baker, B.M. Frey, F.J. Frey, A. Odermatt, The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist, *Mol Cell Endocrinol* 214(1-2) (2004) 27-37.
- [25] L.A. Welberg, J.R. Seckl, M.C. Holmes, Prenatal glucocorticoid programming of brain corticosteroid receptors and corticotrophin-releasing hormone: possible implications for behaviour, *Neuroscience* 104(1) (2001) 71-9.
- [26] L.A. Welberg, J.R. Seckl, M.C. Holmes, Inhibition of 11 β -hydroxysteroid dehydrogenase, the foeto-placental barrier to maternal glucocorticoids, permanently programs amygdala GR

mRNA expression and anxiety-like behaviour in the offspring, *Eur J Neurosci* 12(3) (2000) 1047-54.

[27] R.S. Lindsay, R.M. Lindsay, C.R. Edwards, J.R. Seckl, Inhibition of 11 β -hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring, *Hypertension* 27(6) (1996) 1200-4.

[28] C.S. Wyrwoll, J.R. Seckl, M.C. Holmes, Altered placental function of 11 β -hydroxysteroid dehydrogenase 2 knockout mice, *Endocrinology* 150(3) (2009) 1287-93.

[29] J. Mairesse, J. Lesage, C. Breton, B. Breant, T. Hahn, M. Darnaudery, S.L. Dickson, J. Seckl, B. Blondeau, D. Vieau, S. Maccari, O. Viltart, Maternal stress alters endocrine function of the feto-placental unit in rats, *Am J Physiol Endocrinol Metab* 292(6) (2007) E1526-33.

[30] S.C. Langley-Evans, G.J. Phillips, R. Benediktsson, D.S. Gardner, C.R. Edwards, A.A. Jackson, J.R. Seckl, Protein intake in pregnancy, placental glucocorticoid metabolism and the programming of hypertension in the rat, *Placenta* 17(2-3) (1996) 169-72.

[31] D. Vieau, N. Sebaai, M. Leonhardt, I. Dutriez-Casteloot, O. Molendi-Coste, C. Laborie, C. Breton, S. Deloof, J. Lesage, HPA axis programming by maternal undernutrition in the male rat offspring, *Psychoneuroendocrinology* 32 Suppl 1 (2007) S16-20.

[32] J.R. Seckl, M.C. Holmes, Mechanisms of disease: glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology, *Nat Clin Pract Endocrinol Metab* 3(6) (2007) 479-88.

[33] A. Odermatt, C. Gummy, Glucocorticoid and mineralocorticoid action: why should we consider influences by environmental chemicals?, *Biochem Pharmacol* 76(10) (2008) 1184-93.

[34] T.E. Strandberg, S. Andersson, A.L. Jarvenpaa, P.M. McKeigue, Preterm birth and licorice consumption during pregnancy, *Am J Epidemiol* 156(9) (2002) 803-5.

[35] K. Raikkonen, J.R. Seckl, K. Heinonen, R. Pyhala, K. Feldt, A. Jones, A.K. Pesonen, D.I. Phillips, J. Lahti, A.L. Jarvenpaa, J.G. Eriksson, K.A. Matthews, T.E. Strandberg, E. Kajantie, Maternal prenatal licorice consumption alters hypothalamic-pituitary-adrenocortical axis function in children, *Psychoneuroendocrinology* 35(10) (2010) 1587-93.

[36] K. Raikkonen, A.K. Pesonen, K. Heinonen, J. Lahti, N. Komsu, J.G. Eriksson, J.R. Seckl, A.L. Jarvenpaa, T.E. Strandberg, Maternal licorice consumption and detrimental cognitive and psychiatric outcomes in children, *Am J Epidemiol* 170(9) (2009) 1137-46.

[37] E. Schoof, M. Girstl, W. Frobenius, M. Kirschbaum, H.G. Dorr, W. Rascher, J. Dotsch, Decreased gene expression of 11 β -hydroxysteroid dehydrogenase type 2 and 15-

hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia, *J Clin Endocrinol Metab* 86(3) (2001) 1313-7.

[38] M. Aufdenblatten, M. Baumann, L. Raio, B. Dick, B.M. Frey, H. Schneider, D. Surbek, B. Hoher, M.G. Mohaupt, Prematurity is related to high placental cortisol in preeclampsia, *Pediatr Res* 65(2) (2009) 198-202.

[39] A. Vuorinen, L.G. Nashev, A. Odermatt, J.M. Rollinger, D. Schuster, Pharmacophore Model Refinement for 11 β -Hydroxysteroid Dehydrogenase Inhibitors: Search for Modulators of Intracellular Glucocorticoid Concentrations, *Mol Inform* 33(1) (2014) 15-25.

[40] D. Schuster, E.M. Maurer, C. Laggner, L.G. Nashev, T. Wilckens, T. Langer, A. Odermatt, The discovery of new 11 β -hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening, *J Med Chem* 49(12) (2006) 3454-66.

[41] D.V. Kratschmar, A. Vuorinen, T. Da Cunha, G. Wolber, D. Classen-Houben, O. Doblhoff, D. Schuster, A. Odermatt, Characterization of activity and binding mode of glycyrrhetic acid derivatives inhibiting 11 β -hydroxysteroid dehydrogenase type 2, *J Steroid Biochem Mol Biol* 125(1-2) (2011) 129-42.

[42] A.G. Atanasov, S. Tam, J.M. Rocken, M.E. Baker, A. Odermatt, Inhibition of 11 β -hydroxysteroid dehydrogenase type 2 by dithiocarbamates, *Biochem Biophys Res Commun* 308(2) (2003) 257-62.

[43] C. Furstenberger, A. Vuorinen, T. Da Cunha, D.V. Kratschmar, M. Saugy, D. Schuster, A. Odermatt, The anabolic androgenic steroid fluoxymesterone inhibits 11 β -hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation, *Toxicol Sci* 126(2) (2012) 353-61.

[44] A. Vuorinen, R. Engeli, A. Meyer, F. Bachmann, U.J. Griesser, D. Schuster, A. Odermatt, Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17 β -hydroxysteroid dehydrogenase 2 inhibitors, *J Med Chem* 57(14) (2014) 5995-6007.

[45] P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Fujimoto, N.M. Goeke, B.J. Olson, D.C. Klenk, Measurement of protein using bicinchoninic acid, *Anal Biochem* 150(1) (1985) 76-85.

[46] G. Jones, P. Willett, R.C. Glen, A.R. Leach, R. Taylor, Development and validation of a genetic algorithm for flexible docking, *J Mol Biol* 267(3) (1997) 727-48.

[47] Z.K. Wan, E. Chenail, J. Xiang, H.Q. Li, M. Ipek, J. Bard, K. Svenson, T.S. Mansour, X. Xu, X. Tian, V. Suri, S. Hahm, Y. Xing, C.E. Johnson, X. Li, A. Qadri, D. Panza, M. Perreault,

1
2
3
4 J.F. Tobin, E. Saiah, Efficacious 11 β -hydroxysteroid dehydrogenase type I inhibitors in the diet-
5 induced obesity mouse model, *J Med Chem* 52(17) (2009) 5449-61.
6
7 [48] H. Yamaguchi, T. Akitaya, T. Yu, Y. Kidachi, K. Kamiie, T. Noshita, H. Umetsu, K.
8 Ryoyama, Homology modeling and structural analysis of 11 β -hydroxysteroid dehydrogenase
9 type 2, *Eur J Med Chem* 46(4) (2011) 1325-30.
10
11 [49] H. Yamaguchi, T. Akitaya, Y. Kidachi, K. Kamiie, T. Noshita, H. Umetsu, K. Ryoyama,
12 Mouse 11 β -hydroxysteroid dehydrogenase type 2 for human application: homology modeling,
13 structural analysis and ligand-receptor interaction, *Cancer Inform* 10 (2011) 287-95.
14
15 [50] G. Wolber, T. Langer, LigandScout: 3-D pharmacophores derived from protein-bound
16 ligands and their use as virtual screening filters, *J Chem Inf Model* 45(1) (2005) 160-9.
17
18 [51] A. Meyer, A. Vuorinen, A.E. Zielinska, T. Da Cunha, P. Strajhar, G.G. Lavery, D. Schuster,
19 A. Odermatt, Carbonyl reduction of triadimefon by human and rodent 11 β -hydroxysteroid
20 dehydrogenase 1, *Biochem Pharmacol* 85(9) (2013) 1370-8.
21
22 [52] T. Kaserer, K.R. Beck, M. Akram, A. Odermatt, D. Schuster, Pharmacophore Models and
23 Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on
24 Hydroxysteroid Dehydrogenases, *Molecules* 20(12) (2015) 22799-832.
25
26 [53] A.G. Atanasov, L.G. Nashev, S. Tam, M.E. Baker, A. Odermatt, Organotins disrupt the 11 β -
27 hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids, *Environ*
28 *Health Perspect* 113(11) (2005) 1600-6.
29
30 [54] M.V. Mustonen, V.V. Isomaa, T. Vaskivuo, J. Tapanainen, M.H. Poutanen, F. Stenback,
31 R.K. Vihko, P.T. Vihko, Human 17 β -hydroxysteroid dehydrogenase type 2 messenger
32 ribonucleic acid expression and localization in term placenta and in endometrium during the
33 menstrual cycle, *J Clin Endocrinol Metab* 83(4) (1998) 1319-24.
34
35 [55] J. Takeyama, H. Sasano, T. Suzuki, K. Iinuma, H. Nagura, S. Andersson, 17 β -
36 hydroxysteroid dehydrogenase types 1 and 2 in human placenta: an immunohistochemical study
37 with correlation to placental development, *J Clin Endocrinol Metab* 83(10) (1998) 3710-5.
38
39 [56] S. Arampatzis, B. Kadereit, D. Schuster, Z. Balazs, R.A. Schweizer, F.J. Frey, T. Langer, A.
40 Odermatt, Comparative enzymology of 11 β -hydroxysteroid dehydrogenase type 1 from six
41 species, *J Mol Endocrinol* 35(1) (2005) 89-101.
42
43 [57] A.G. Atanasov, I.D. Ignatova, L.G. Nashev, B. Dick, P. Ferrari, F.J. Frey, A. Odermatt,
44 Impaired protein stability of 11 β -hydroxysteroid dehydrogenase type 2: a novel mechanism of
45 apparent mineralocorticoid excess, *J Am Soc Nephrol* 18(4) (2007) 1262-70.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- [58] P. Ferrari, R.E. Smith, J.W. Funder, Z.S. Krozowski, Substrate and inhibitor specificity of the cloned human 11 β -hydroxysteroid dehydrogenase type 2 isoform, *Am J Physiol* 270(5 Pt 1) (1996) E900-4.
- [59] D. Schuster, 3D pharmacophores as tools for activity profiling, *Drug Discov Today Technol* 7(4) (2010) 205-211.
- [60] L.G. Nashev, A. Vuorinen, L. Praxmarer, B. Chantong, D. Cereghetti, R. Winiger, D. Schuster, A. Odermatt, Virtual screening as a strategy for the identification of xenobiotics disrupting corticosteroid action, *PLoS One* 7(10) (2012) e46958.
- [61] S. Diederich, C. Grossmann, B. Hanke, M. Quinkler, M. Herrmann, V. Bahr, W. Oelkers, In the search for specific inhibitors of human 11 β -hydroxysteroid-dehydrogenases (11 β -HSDs): chenodeoxycholic acid selectively inhibits 11 β -HSD-I, *Eur J Endocrinol* 142(2) (2000) 200-7.
- [62] M.I. Morris, Posaconazole: a new oral antifungal agent with an expanded spectrum of activity, *Am J Health Syst Pharm* 66(3) (2009) 225-36.
- [63] N.H. Georgopapadakou, T.J. Walsh, Antifungal agents: chemotherapeutic targets and immunologic strategies, *Antimicrob Agents Chemother* 40(2) (1996) 279-91.
- [64] L. Willems, R. van der Geest, K. de Beule, Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics, *J Clin Pharm Ther* 26(3) (2001) 159-69.
- [65] A. Ghosal, N. Hapangama, Y. Yuan, J. Achanfuo-Yeboah, R. Iannucci, S. Chowdhury, K. Alton, J.E. Patrick, S. Zbaida, Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil), *Drug Metab Dispos* 32(2) (2004) 267-71.
- [66] N. Isoherranen, K.L. Kunze, K.E. Allen, W.L. Nelson, K.E. Thummel, Role of itraconazole metabolites in CYP3A4 inhibition, *Drug Metab Dispos* 32(10) (2004) 1121-31.
- [67] D. Wexler, R. Courtney, W. Richards, C. Banfield, J. Lim, M. Laughlin, Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study, *Eur J Pharm Sci* 21(5) (2004) 645-53.
- [68] C.C. Peng, I. Templeton, K.E. Thummel, C. Davis, K.L. Kunze, N. Isoherranen, Evaluation of 6 β -hydroxycortisol, 6 β -hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo, *Clin Pharmacol Ther* 89(6) (2011) 888-95.
- [69] L.M. Vermeer, C.D. Isringhausen, B.W. Ogilvie, D.B. Buckley, Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro

Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters, *Drug Metab Dispos* 44(3) (2016) 453-9.

[70] A.H. Saad, D.D. DePestel, P.L. Carver, Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants, *Pharmacotherapy* 26(12) (2006) 1730-44.

[71] M. Ceckova-Novotna, P. Pavek, F. Staud, P-glycoprotein in the placenta: expression, localization, regulation and function, *Reprod Toxicol* 22(3) (2006) 400-10.

[72] P.J. Mark, B.J. Waddell, P-glycoprotein restricts access of cortisol and dexamethasone to the glucocorticoid receptor in placental BeWo cells, *Endocrinology* 147(11) (2006) 5147-52.

[73] T. Denolle, M. Azizi, C. Massart, M.C. Zennaro, Itraconazole: a new drug-related cause of hypertension, *Ann Cardiol Angeiol (Paris)* 63(3) (2014) 213-5.

[74] P.K. Sharkey, M.G. Rinaldi, J.F. Dunn, T.C. Hardin, R.J. Fetchick, J.R. Graybill, High-dose itraconazole in the treatment of severe mycoses, *Antimicrob Agents Chemother* 35(4) (1991) 707-13.

[75] Janssen-Cilag-AG, Sporanox drug safety sheet, (2015).

[76] MSD-MERCK-SHARP&DOHME-AG, NOXAFIL Inf Konz 18 mg/ml drug safety sheet, (2014).

[77] R. Courtney, S. Pai, M. Laughlin, J. Lim, V. Batra, Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults, *Antimicrob Agents Chemother* 47(9) (2003) 2788-95.

[78] J.E. Conte, Jr., J.A. Golden, G. Krishna, M. McIver, E. Little, E. Zurlinden, Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects, *Antimicrob Agents Chemother* 53(2) (2009) 703-7.

[79] M. De Santis, E. Di Gianantonio, E. Cesari, G. Ambrosini, G. Straface, M. Clementi, First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy, *Drug Saf* 32(3) (2009) 239-44.

[80] B. Bar-Oz, M.E. Moretti, G. Mareels, T. Van Tittelboom, G. Koren, Reporting bias in retrospective ascertainment of drug-induced embryopathy, *Lancet* 354(9191) (1999) 1700-1.

[81] B. Bar-Oz, M.E. Moretti, R. Bishai, G. Mareels, T. Van Tittelboom, J. Verspeelt, G. Koren, Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study, *Am J Obstet Gynecol* 183(3) (2000) 617-20.

- [82] K.E. Murphy, M.E. Hannah, A.R. Willan, S.A. Hewson, A. Ohlsson, E.N. Kelly, S.G. Matthews, S. Saigal, E. Asztalos, S. Ross, M.F. Delisle, K. Amankwah, P. Guselle, A. Gafni, S.K. Lee, B.A. Armson, Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial, *Lancet* 372(9656) (2008) 2143-51.
- [83] R.J. Wapner, Y. Sorokin, E.A. Thom, F. Johnson, D.J. Dudley, C.Y. Spong, A.M. Peaceman, K.J. Leveno, M. Harper, S.N. Caritis, M. Miodovnik, B. Mercer, J.M. Thorp, A. Moawad, M.J. O'Sullivan, S. Ramin, M.W. Carpenter, D.J. Rouse, B. Sibai, S.G. Gabbe, Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy, *Am J Obstet Gynecol* 195(3) (2006) 633-42.
- [84] E. Bevilacqua, R. Brunelli, M.M. Anceschi, Review and meta-analysis: Benefits and risks of multiple courses of antenatal corticosteroids, *J Matern Fetal Neonat* 23(4) (2010) 244-60.
- [85] M.J. Nyirenda, R.S. Lindsay, C.J. Kenyon, A. Burchell, J.R. Seckl, Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring, *J Clin Invest* 101(10) (1998) 2174-81.
- [86] V.M. Heine, D.H. Rowitch, Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11β -HSD2-dependent mechanism, *J Clin Invest* 119(2) (2009) 267-77.
- [87] J. Kim, J.Y. Tang, R. Gong, J.J. Lee, K.V. Clemons, C.R. Chong, K.S. Chang, M. Fereshteh, D. Gardner, T. Reya, J.O. Liu, E.H. Epstein, D.A. Stevens, P.A. Beachy, Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth, *Cancer Cell* 17(4) (2010) 388-99.
- [88] J.R. Pace, A.M. DeBerardinis, V. Sail, S.K. Tacheva-Grigorova, K.A. Chan, R. Tran, D.S. Raccuia, R.J. Wechsler-Reya, M.K. Hadden, Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic, *J Med Chem* 59(8) (2016) 3635-49.
- [89] B. Chen, V. Trang, A. Lee, N.S. Williams, A.N. Wilson, E.H. Epstein, Jr., J.Y. Tang, J. Kim, Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma, *Mol Cancer Ther* 15(5) (2016) 866-76.
- [90] C.R. Chong, J. Xu, J. Lu, S. Bhat, D.J. Sullivan, Jr., J.O. Liu, Inhibition of angiogenesis by the antifungal drug itraconazole, *ACS Chem Biol* 2(4) (2007) 263-70.

[91] R. Del Carratore, A. Carpi, P. Beffy, V. Lubrano, L. Giorgetti, B.E. Maserti, M.A. Carluccio, M. Simili, G. Iervasi, S. Balzan, Itraconazole inhibits HMEC-1 angiogenesis, *Biomed Pharmacother* 66(4) (2012) 312-7.

[92] E.V. Khankin, C. Royle, S.A. Karumanchi, Placental vasculature in health and disease, *Semin Thromb Hemost* 36(3) (2010) 309-20.

Figure Legends

Fig. 1. Pharmacophore model used for virtual screening of the DrugBank database. (A) The model consists of four hydrophobic (H) features (cyan), two hydrogen bond acceptors (HBA, green) and a sterical shape restriction (grey) [39]. (B) Virtual hits from the DrugBank screening fitted into the model. Compounds are color-coded: red – tioconazole; green – butoconazole; violet – sertaconazole.

Fig. 2. Structure-activity relationship of azole fungicides inhibiting 11 β -HSDs. 11 β -HSD1-dependent reduction of cortisone (200 nM) to cortisol and 11 β -HSD2-dependent oxidation of cortisol (200 nM) to cortisone were measured using HEK-293 cell lysates in the presence of 500 μ M NADPH or NAD⁺, respectively. Residual enzyme activity upon exposure to 20 μ M test substance (mean $\pm$ SD) and IC₅₀ values (mean $\pm$ SD) were obtained from three independent experiments. For compounds with residual enzyme activities (% of control) >40%, at a compound concentration of 20 μ M, IC₅₀ values were not determined (n.d.). **a**, values reported earlier by Vuorinen et al. [39].

Fig. 3. Inhibition of 11 β -HSD2 enzyme activity determined in HEK-293 cell lysates. Lysates of HEK-293 cells stably expressing recombinant human 11 β -HSD2 were incubated for 10 min at 37°C with 200 nM radiolabeled cortisol, 500 μ M NAD⁺ and increasing concentrations of itraconazole (A), hydroxyitraconazole (OHI) (B) and posaconazole (C). The substrate conversion was determined and compared to the enzyme activity in the control samples (0.1% DMSO). Data represent mean $\pm$ SD from three independent experiments.

Fig. 4. Inhibition of rat and mouse 11 β -HSD2 activity measured in kidney homogenates, compared to human 11 β -HSD2 in HEK-293 cell lysates. Rat and mouse kidney homogenates were incubated for 20 min at 37°C with 50 nM radiolabeled corticosterone in the absence or presence of 10 μ M itraconazole (A), 10 μ M hydroxyitraconazole (OHI) (B) or 10 μ M posaconazole (C). Human 11 β -HSD2 activity was measured in HEK-293 cells stably expressing recombinant human 11 β -HSD2 upon incubation for 10 min at 37°C with 200 nM radiolabeled cortisol, 500 μ M NAD⁺ and the corresponding concentration of azole fungicide (10 μ M itraconazole, 10 μ M posaconazole or 5 μ M OHI). The substrate conversion was calculated (in nmoles/min) and normalized to the enzyme activity in the control sample (0.1% DMSO). Data represent mean $\pm$ SD from at least three independent experiments. **a**, 5 μ M was used (due to complete inhibition higher concentrations were not analyzed).

Fig. 5. Predicted binding of selected fungicides to 11 β -HSD1 and 11 β -HSD2. (A) Representative binding poses of inhibitors in human 11 β -HSD1 exemplified by tioconazole and sertaconazole. Important interactions for protein-ligand binding and the cofactor are shown in ball-and-stick style. Hydrophobic contacts between the ligand and the binding site are represented as yellow spheres, the HBA to Ala172 as red arrow and the aromatic stacking with Tyr183 as blue circle. (B) Binding mode of itraconazole docked into the homology model of human 11 β -HSD2. (C) Itraconazole docked into the homology model of murine 11 β -HSD2. Arg279 (equivalent to Arg212 in human 11 β -HSD2) is pointing away from the binding pocket, while Trp276 blocks the binding pocket next to the cofactor NADPH. (D) Itraconazole docked into the homology model of murine 11 β -HSD2. The ligand is not anchored via hydrogen bonds or charged interactions, only hydrophobic contacts (yellow spheres) are formed. (E) Posaconazole (grey) and OHI (green) docked into murine 11 β -HSD2. Their hydroxyl groups form hydrogen

bonds (green arrow) with the cofactor, which provides an explanation for their higher activity compared to itraconazole.

Figure1
[Click here to download high resolution image](#)

Figure2
[Click here to download high resolution image](#)

compound	structure	residual enzyme activity [% of control] (20 μM)		IC ₅₀ values [μM]	
		11β-HSD1	11β-HSD2	11β-HSD1	11β-HSD2
Albendazole		105 ± 5	100 ± 15	n.d.	n.d.
Climbazole		57 ± 10	86 ± 12	n.d.	n.d.
Tioconazole		18 ± 3	44 ± 5	4.97 ± 0.64	n.d.
Sertaconazole		35 ± 3	61 ± 5	12.73 ± 1.69	n.d.
Butoconazole		48 ± 6	50 ± 6	n.d.	n.d.
Ketoconazole		67 ± 4 ^a	26 ± 2 ^a	n.d.	n.d.
Terconazole		97 ± 6	62 ± 5	n.d.	n.d.
Posaconazole		88 ± 11	8 ± 5	n.d.	0.460 ± 0.098
Itraconazole		89 ± 6	4 ± 3	n.d.	0.139 ± 0.014

Figure3
[Click here to download high resolution image](#)

Figure4
[Click here to download high resolution image](#)

Figure5
[Click here to download high resolution image](#)